Key regions: Australia, Japan, United States, Germany, Europe
The Anti-Coagulants market in CIS has been experiencing significant growth in recent years, with several trends and developments contributing to this growth.
Customer preferences: One of the main drivers of growth in the Anti-Coagulants market in CIS is the increasing prevalence of cardiovascular diseases in the region. As a result, there is a growing demand for drugs that can help prevent blood clots and reduce the risk of heart attacks and strokes. Additionally, there is a growing awareness among patients and healthcare providers of the benefits of using Anti-Coagulants to manage these conditions.
Trends in the market: One of the key trends in the Anti-Coagulants market in CIS is the shift towards newer, more advanced drugs. While traditional Anti-Coagulants such as Warfarin continue to be widely used, newer drugs such as Dabigatran and Rivaroxaban are gaining popularity due to their improved safety and efficacy profiles. Additionally, there is a growing trend towards using combination therapies to manage cardiovascular diseases, which is driving demand for drugs that can be used in combination with Anti-Coagulants.
Local special circumstances: One of the unique characteristics of the Anti-Coagulants market in CIS is the relatively low cost of drugs in the region. This has made these drugs more accessible to a wider range of patients, particularly those with limited financial resources. Additionally, there are a number of local manufacturers in the region that are producing Anti-Coagulants, which has helped to reduce prices further and increase availability.
Underlying macroeconomic factors: The growth of the Anti-Coagulants market in CIS is also being driven by a number of underlying macroeconomic factors. These include the increasing prevalence of cardiovascular diseases in the region, as well as the growing awareness among patients and healthcare providers of the benefits of using Anti-Coagulants to manage these conditions. Additionally, the relatively low cost of drugs in the region and the presence of local manufacturers are helping to drive demand and increase availability. Overall, these factors are expected to continue to fuel growth in the Anti-Coagulants market in CIS in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
